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Abstract: Aldosterone-producing adenomas with somatic mutations in the KCNJ5 G-protein-coupled
inwardly rectifying potassium channel are a cause of primary aldosteronism. These mutations drive al-
dosterone excess, but their role in cell growth is undefined. Our objective was to determine the role
of KCNJ5 mutations in adrenal cell proliferation and apoptosis. The Ki67 proliferative index was pos-
itively correlated with adenoma diameter in aldosterone-producing adenomas with a KCNJ5 mutation
(r=0.435, P=0.007), a negative correlation was noted in adenomas with no mutation detected (r=-0.548,
P=0.023). Human adrenocortical cell lines were established with stable expression of cumate-inducible
wild-type or mutated KCNJ5. Increased cell proliferation was induced by low-level induction of KCNJ5-
T158A expression compared with control cells (P=0.009), but increased induction ablated this difference.
KCNJ5-G151R displayed no apparent proliferative effect, but KCNJ5-G151E and L168R mutations each
resulted in decreased cell proliferation (difference P<0.0001 from control cells, both comparisons). Under
conditions tested, T158A had no effect on apoptosis, but apoptosis increased with expression of G151R
(P<0.0001), G151E (P=0.008), and L168R (P<0.0001). We generated a specific KCNJ5 monoclonal an-
tibody which was used in immunohistochemistry to demonstrate strong KCNJ5 expression in adenomas
without a KCNJ5 mutation and in the zona glomerulosa adjacent to adenomas irrespective of geno-
type as well as in aldosterone-producing cell clusters. Double immunofluorescence staining for KCNJ5
and CYP11B2 (aldosterone synthase) showed markedly decreased KCNJ5 immunostaining in CYP11B2-
positive cells compared with CYP11B2-negative cells in aldosterone-producing adenomas with a KCNJ5
mutation. Together, these findings support the concept that cell growth effects of KCNJ5 mutations are
determined by the expression level of the mutated channel.
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Unilateral primary aldosteronism (PA) is the most preva-lent surgically-correctable form of hypertension. The 
constitutive production of aldosterone mainly originates from 
a unilateral aldosterone-producing adenoma (APA) and less 
often from unilateral hyperplasia (30% and 2% of cases of 
PA, respectively).1 Major breakthroughs in understanding the 
pathophysiology of sporadic APAs have been made since the 
identification by Choi et al2 of somatic mutations in the KCNJ5 
gene (causing KCNJ5-G151R or KCNJ5-L168R missense 
mutations) in a high proportion of these tumors.2–4 KCNJ5 is 
an inwardly rectifying potassium channel (also called GIRK4, 
[G protein-coupled inwardly rectifying potassium channel]) 
and the described mutations cause sodium ion conductance 
due to the loss of selectivity for potassium ions by the chan-
nel pore. In adrenocortical cells, the consequent membrane 
depolarization triggers opening of voltage-gated calcium 
channels and calcium ion influx ultimately activates aldoste-
rone production.2,5
The identification of additional APA somatic mutations 
in the CACNA1D (Cav1.3 calcium channel) and in the Na+/
K+-ATPase and Ca2+-ATPase ion transporters (ATP1A1 and 
ATP2B3, respectively) highlighted the importance of intra-
cellular ion homeostasis and calcium signaling in aldoste-
rone production6,7 and, together with somatic mutations in 
CTNNB1 (β-catenin), these mutations can be detected in 
almost 90% of APAs.8 In most populations, a predominance 
of KCNJ5 mutations in APAs over other genotypes is re-
ported3,4,9–11 with a global prevalence of 43%.12
A role for KCNJ5 mutations in adrenal cell growth has 
not been defined. When initially described, KCNJ5 mutations 
were proposed to result in both constitutive aldosterone pro-
duction and cell proliferation2 due to the established role of 
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calcium signaling in both processes.13,14 A function in driv-
ing aldosterone excess has been demonstrated by expression 
of mutated forms of KCNJ5 in human adrenocortical cells in 
vitro5 but a decrease in cell proliferation resulted from expres-
sion of KCNJ5-T158A.5 This mutation (KCNJ5-T158A) has 
been identified in both sporadic APAs and a familial form of 
PA (called familial hyperaldosteronism type III)2,15 and the ab-
sence of an effect on cell proliferation in vitro is seemingly 
paradoxical to the massive cortical hyperplasia observed in a 
patient carrying the germline variant.2,16
Aldosterone-producing cell clusters (APCC) are a histo-
pathologic feature often found beneath the adrenal capsule 
under normal and pathological conditions.17 APCCs com-
prise tight nests of predominantly zona glomerulosa cells 
with intense immunohistochemistry staining for CYP11B2 
(aldosterone synthase). A notable proportion of APCCs carry 
mutations in CACNA1D, ATP1A1, and ATP2B3, but KCNJ5 
mutations are curiously absent.17,18 Our objective was to estab-
lish the effects of KCNJ5 mutations on cell growth in human 
adrenocortical cells by specifically addressing their roles in 
cell proliferation and apoptosis.
Methods
The data that support the findings of this study are available from the 
corresponding author on reasonable request.
Patient Samples
The study included 72 surgically resected adrenals from patients 
diagnosed with unilateral PA according to the Endocrine Society 
Guideline.19 Patients were screened for PA using the plasma aldo-
sterone-to-direct renin concentration ratio, and diagnosis was con-
firmed by the intravenous saline load test according to local criteria.20 
Adenoma size was assessed from the diameter of the largest nodule 
at pathology, and CYP11B2 immunohistochemistry was done on all 
adrenals, and any without a well-circumscribed CYP11B2-positive 
adenoma were excluded. All participants gave written informed con-
sent, and the protocol was approved by the local ethics committee.
DNA Sequencing
Genomic DNA was extracted from dissected nodules from fresh 
frozen adrenal tissues, and DNA fragments were amplified using 
primers flanking mutation hot spot regions in KCNJ5, ATP1A1, 
ATP2B3, and CACNA1D before DNA sequencing as described 
elsewhere.21
Production of HAC15 Stable Cells Lines With 
Inducible KCNJ5 Expression
cDNAs encoding mutated and wild-type forms of KCNJ5 were pre-
pared by Gateway cloning (ThermoFisher Scientific) in cumate-
inducible PiggyBac vectors (System Biosciences, Palo Alto, CA). 
Stable cell lines were established by cotransfection of human adre-
nocortical cells (HAC15 cells, a kind gift from Professor William 
E. Rainey, University of Michigan, Ann Arbor) with the PiggyBac 
vector (carrying the human KCNJ5 cDNA) and the Super PiggyBac 
transposase according to the manufacturer´s instructions (System 
Biosciences, Palo Alto, CA). Transfected cells were selected with 
puromycin (4 µg/mL) in the presence of verapamil (10 µmol/L) to 
inhibit the P glycoprotein.22 The macrolide antibiotic roxithromycin 
(20 µmol/L) was also included to inhibit any potential effects on cell 
growth of mutant KCNJ5 channels23 in the absence of the cumate 
inducer. Total RNA was extracted from stable cell lines after induc-
tion with cumate (10 µg/mL) for 72 hours, reverse transcribed and 
the KCNJ5 gene was sequenced to confirm the mutated or wild-type 
KCNJ5 genotype of all cell lines.21
Cell Proliferation and Apoptosis Assays
HAC15 cells (2.5×104 cells/well) stably transfected with wild-type 
or mutated forms of KCNJ5 (T158A, G151R, G151E, or L168R) or 
empty vector were plated in 96-well plates, and transcription was in-
duced with 1 µg/mL or 10 µg/mL cumate in the absence of roxithro-
mycin for 24 hours. Cell proliferation was determined with a WST-1 
(water-soluble tetrazolium salt-1) assay (Roche), and apoptosis was 
quantified by an Annexin V apoptosis assay (Promega).
Generation of Monoclonal Antibodies Against 
Human KCNJ5
A peptide corresponding to the N-terminal portion of human KCNJ5 
(acetyl-36-ATDRTRLLAEGKKP-49-C) with the addition of a 
cysteine at the C-terminal end was synthesized by LifeTein LLC 
(Hillsborough, NJ) and conjugated to 5 mg of ImjectTM Blue Carrier 
Protein (ThermoFisher Scientific) using Succinimidyl-6-(iodoacetyl)
aminocaproate (Molecular Biosciences [Boulder], CO). Four Swiss 
Webster Female mice were immunized initially with 10 µg of immu-
nogen with Complete Freund’s Adjuvant (Millipore-Sigma) followed 
by immunization using incomplete Freund’s adjuvant every 2 weeks. 
After 2 months of biweekly immunizations, the mice received the 
immunogen in saline intraperitoneally, and 3 days later were eutha-
nized using isofluorane anesthesia, blood was withdrawn and spleens 
removed under aseptic conditions. Spleen cells were then obtained 
and frozen in liquid nitrogen using DMEM media containing 20% 
newborn calf serum, 5% dimethylsulfoxide, and 2.5% of polyeth-
ylene glycol 1000.
After titers were performed on the serum, the spleen from 
the mouse with the higher titer was fused with polyethylene gly-
col 1450 (ATCC.org) to the mouse myeloma SP2-mIL6-hIL21-
hTERT cells and plated into 10×96 well plates. After 10 days, the 
wells were screened by ELISA on plates coated with the acetyl-
36-ATDRTRLLAEGKKP-49-C conjugated to chicken ovalbumin. 
Positive clones were then screened by Western blotting of cell ly-
sates from human embryonic kidney 293T cells transduced with a 
tetracycline-inducible lentivirus containing the human KCNJ5 se-
quence.5 Clones which gave single bands of the appropriate mo-
lecular mass for KCNJ5 on Western blots were subcloned using 
high-density methyl cellulose24 and were isotyped. The use of mice 
for the generation of monocloncal antibodies was approved by the 
University of Mississippi Medical Center IACUC.
Immunohistochemistry and Immunofluorescence
Formalin-fixed paraffin-embedded adrenal tissue sections (3 µm) 
were used for CYP11B2 immunohistochemistry to detect aldoste-
rone synthase expression with a monoclonal antibody (clone 17B) 
diluted 1:200 as described,25 and KCNJ5 immunohistochemistry was 
performed using the KCNJ5 monoclonal antibody generated herein 
(clone No. 36-33-5, dilution 1:2000). Double immunofluorescence 
CYP11B2 and KCNJ5 staining used an anti-mouse IgG1 Alexa Fluor 
488 secondary antibody (to detect CYP11B2 primary antibody) and 
anti-mouse IgG2B Alexa Fluor 594 (to detect KCNJ5 antibodies) both 
diluted 1:200 (Invitrogen). A rabbit anti-PARP (poly-ADP ribose pol-
ymerase) monoclonal antibody diluted 1:2000 (Cell Signaling) was 
used for immunofluorescence staining of cleaved PARP with an anti-
rabbit Alexa Fluor 594 secondary antibody diluted 1:200 (Invitrogen).
Scoring Adrenals for Ki67 Proliferation Index and 
KCNJ5 Immunostaining
Ki67 immunohistochemistry was performed on formalin-fixed par-
affin-embedded adrenal sections (3 µm) using a rabbit monoclonal 
antibody (clone No. SP6 1:200 dilution, Sigma-Aldrich). The Ki67 
proliferation index was assessed as the percentage of the manual 
count of intense Ki67 stained nuclei relative to the total hematoxylin 
stained nuclei which were quantified by color segmentation using 
ImageJ software. Three separate fields of view were used for scor-
ing, and the final proliferation index was calculated as the average 
of the 3 Ki67 scores.26 To score KCNJ5 immunostaining intensity 
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score system was used in which intensity of immunohistochemis-
try staining was graded 0 to 4 for undetectable, low, moderate, or 
high27 from a field of view at ×20 magnification acquired from each 
adrenal sample. Both the Ki67 proliferation index and H scores for 
CYP11B2 were evaluated by researchers blinded to mutational status 
and pathological reports of the assessed adrenals (H. Schneider and T. 
Ann Williams). Adenoma sizes (to determine correlations with Ki67 
index) were determined by the pathologist (T. Knösel) as the diameter 
of the largest nodule.
Statistical Analyses
Statistical analyses were performed using SPSS, version 25.0 and 
Graphpad Prism version 7.0.
Comparisons between 2 groups were determined using a t test 
or a Mann-Whitney U test, multiple comparisons were analyzed by 
ANOVA with a Bonferroni test or Kruskal-Wallis tests with pairwise 
comparisons. Pearson correlation coefficients were used to analyze 
univariate correlations. P<0.05 was considered significant.
Results
Clinical Characteristics of Patients With APA 
According to Genotype
Genotyping of 72 resected adrenals from patients with an 
APA, determined 39 APAs with a KCNJ5 mutation (L168R, 
n=22; G151R, n=16, and T158A, n=1), 5 with a CACNA1D 
mutation, and 3 and 2 APAs with ATP1A1 or ATP2B3 muta-
tions, respectively. The remaining 23 APAs did not carry a 
mutation in known hotspots of target genes and were referred 
to as tumors with no mutation detected (NMD).
Patients with a KCNJ5-mutated APA were younger than 
patients with an NMD-APA (47.2 years±10.4 versus 57.7 
years±11.0; P=0.001) with a higher proportion of women 
than patients with an NMD-APA (82.1% of 39 patients 
versus 30.4% of 23; P<0.001) or relative to the small group 
of patients with other somatic APA mutations (10.0% of 10 
patients; P<0.001). The largest adenoma diameter at pa-
thology was greater in KCNJ5-mutated APAs (17.0 mm 
[14.0–24.0]) compared with both NMD-APAs and APAs with 
other mutations combined (12.0 mm [8.0–25.0], P=0.019 and 
9.0 mm [7.8–15.3], P=0.003, respectively). We noted a lower 
PAC in KCNJ5-mutated APAs compared with the group of 
APAs with a mutation in ATP1A1, ATP2B3, and CACNA1D 
combined (979 pmol/L [500–1470] compared with 1989 
pmol/L [1624–3346], P=0.006; Table S1 in the online-only 
Data Supplement).
Diverse Proliferation in Adenomas With or Without 
a KCNJ5 Mutation
Ki67 proliferation index was assessed in a subset of adrenals 
(37 APAs with KCNJ5 mutations; 17 designated NMD and 
10 with either a CACNA1D, ATP1A1, or ATP2B3 mutation). 
Adenoma size was larger in APAs with a KCNJ5 mutation 
compared with NMD (17.0 mm [14.5–24.5] versus 12.0 
mm [8.0–27.5], P=0.0327). APAs with a KCNJ5 mutation 
had a lower proliferation index relative to APAs with NMD 
(0.9%±0.4 versus 1.2%±0.4, P=0.011). The Ki67 prolifera-
tion index was positively correlated with adenoma diameter in 
KCNJ5-mutated APAs (r=0.4347, P=0.0072) in contrast to the 
negative linear correlation noted in NMD-APAs (r=−0.5484, 
P=0.0226; Figure 1). There was no correlation of adenoma 
diameter with Ki67 index in the small group of APAs with a 
CACNA1D, ATP1A1, or ATP2B3 mutation combined. There 
was no significant difference in adenoma diameter between 
APAs with a L168R or a G151R mutation (L168R, 16.0 mm 
[15.0–27.3] versus G151R, 18.0 mm [14.0–22.0]; P=0.636) 
or in Ki67 score (L168R, 1.0%±0.4 versus G151R, 0.8%±0.4; 
P=0.339).
Effects of KCNJ5 Mutations on Cell Growth in 
Adrenocortical Cells
Stable HAC15 cell lines expressing KCNJ5 with different 
genotypes were established using the selection marker puro-
mycin. Sensitivity to puromycin was increased in the pres-
ence of verapamil (10 μmol/L; Figure S1), and the presence of 
KCNJ5 mutations was confirmed by Sanger sequencing. The 
cell viability of the KCNJ5-T158A HAC15 cell line was sig-
nificantly higher compared with control cells (transfected with 
empty vector) after 24-hour induction with 1 μg/mL cumate 
(P=0.0094). This effect on cell proliferation was absent in cells 
with increased transcriptional induction of KCNJ5-T158A (10 
μg/mL cumate). KCNJ5-G151R had no apparent effect on 
adrenocortical proliferation in vitro, whereas decreased pro-
liferation was observed in HAC15 cells with KCNJ5-G151E 
and L168R mutations (P<0.0001 versus control cells, both 
comparisons; Figure 2A).
Higher levels of cell death by apoptosis were observed 
in cells with KCNJ5-G151R, G151E, and L168R mutations 
(P<0.0001, P=0.0078, and P<0.0001 versus control cells, re-
spectively) under the conditions tested (24-hour incubation 
with 1 µg/mL cumate). Cells carrying the KCNJ5-T158A 
mutation did not induce apoptosis under the same conditions 
(Figure 2B). These observations were consistent with immu-
nofluorescence detection of cleaved PARP, a hallmark of ap-
optosis, which showed increased numbers cells with positive 
cleaved PARP staining in the nuclei of KCNJ5-G151E and 
L168R transfected cells compared with control cells (Figure 
S2). HAC15 cells with KCNJ5-T158A and G151R mutations 
displayed a similar proportion of cleaved-PARP positive cells 
compared with control cells (Figure S2).
Generation of Monoclonal Antibodies Against 
Human KCNJ5
There were 100 positive clones from the ELISA screen and of 
these, 2 clones (No. 33 and No. 68) displayed specific bind-
ing to KCNJ5 on Western blots of human embryonic kidney 
293T cell lysates transduced with a lentivirus carrying the 
human KCNJ5 sequence. Clones No. 33 and No. 68 were 
subcloned to produce antibodies KCNJ5-33–5 and KCNJ5-
68-15, and their specificity was validated by Western blotting 
(Figure 3A). The 2 clones were isotyped, clone KCNJ5-33–5 
was IgG2b, and the KCNJ5-68-15 was IgG2c. Both antibod-
ies were used for immunohistochemistry of formalin-fixed 
paraffin-embedded sections of resected adrenals from patients 
with an APA. Analysis of the cortical tissue adjacent to an ade-
noma demonstrated membrane and cytoplasmic staining with 
No. 68-15 quite diffuse throughout the cortex compared with 
predominant plasma membrane staining of zona glomerulosa 
cells with No. 33–5 (Figure 3B through 3C). Clone No. 33–5 
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KCNJ5 Expression in APAs Varies According to 
Genotype
Immunohistochemistry using the KCNJ5 No. 33–5 mono-
clonal antibody was performed on 33 adrenal samples with 
various APA genotypes (KCNJ5, n=13; WT, n=10; CACNA1D, 
n=5; ATP1A1, n=3; and ATP2B3, n=2). Adenomas of all 
adrenals showed positive-immunostaining for KCNJ5 and 
CYP11B2 (Figure 4, Figure S3) with decreased intensity 
of KCNJ5 immunostaining in APAs with KCNJ5 mutations 
compared with other adenomas (Figure 4). Semi-quantitative 
H score assessment of KCNJ5 immunostaining highlighted 
the decreased KCNJ5 expression in APAs with a KCNJ5 mu-
tation (Figure 5A, difference P<0.0001 for KCNJ5-mutated 
APAs versus NMD-APAs and APAs with ATP1A1, ATP2B3, 
CACNA1D mutations combined). There were no apparent dif-
ferences in KCNJ5 immunostaining intensity between NMD-
APAs versus APAs with CACNA1D, ATP1A1, and ATP2B3 
mutations (Figure 4, Figure 5A). No differences in intensity 
of KCNJ5 immunostaining were apparent between APAs 
with different KCNJ5 mutations (KCNJ5-G151R, L168R, or 
T158A; Figure S3).
KCNJ5 immunostaining was lower in all 13 tumors with 
KCNJ5 mutations compared with the paired adjacent cortex 
(Figure 4A and 4B, Figure 5B). In contrast, the majority of 
APAs with other genotypes showed either increased or sim-
ilar KCNJ5 immunostaining intensity in adenomas (75% of 
20 adrenals; Figure 4C, Figure 5B).
Double KCNJ5-CYP11B2 immunofluorescence was 
performed on APAs of different genotypes. Colocalization 
of KCNJ5 with CYP11B2 was demonstrated in all adrenals, 
but a decrease of KCNJ5 immunostaining was evident in 
CYP11B2-positive cells relative to CYP11B2-negative cells 
of the same adenoma carrying a KCNJ5 mutation (Figure 4D, 
Figure S4). This difference of KCNJ5 immunostaining inten-
sity was absent in APAs of other genotypes (Figure S4).
Expression of KCNJ5 in APCCs
KCNJ5 and CYP11B2 immunohistochemistry and double 
KCNJ5-CYP11B2 immunofluoresence of APCCs showed 
moderate to high expression of KCNJ5 in APCCs (n=11; 
Figure 6A) and the colocalization of the high-level KCNJ5 
and CYP11B2 immunostaining (Figure 6B).
Discussion
We demonstrate the diverse effects of KCNJ5 mutations 
on adrenocortical cell growth. We show an increase in 
Figure 1. Correlation of Ki67 score with nodule diameter according to genotype. Ki67 score was positively linearly correlated with aldosterone-producing 
adenoma (APA) diameter in KCNJ5-mutated APAs (r=0.4347, P=0.0072; A), whereas a linear negative correlation was observed in the group of tumors with 
no mutation detected (no mutation detected; r=−0.5484, P=0.0226; B). Ki67 index was not correlated with adenoma diameter in the small group of APAs 
with a CACNA1D [Cav1.3 calcium channel], ATP1A1, or ATP2B3 mutation combined (C). Ki67 score was derived using ImageJ software and calculated 
from the average intense Ki67 nuclei staining count divided by the total nuclei hematoxylin staining count from 3 fields of view. Lines represent the Pearson 
correlation (thick black line) and 95% CI (thin gray line). When the outlier in A is omitted, a positive linear correlation between Ki67 index and APA diameter is 
still observed (r=0.5454, P=0.0006).
Figure 2. Effects of KCNJ5 mutants on cell growth in adrenocortical cells. Human adrenocortical cells (HAC15) cells stably transfected with wild-type or 
mutated forms of KCNJ5 (T158A, G151R, G151E, or L168R) or empty vector (control) were used to measure cell viability (A) or apoptosis (B). Cell viability 
was measured using a WST-1 (water-soluble tetrazolium salts) proliferation assay after 24-hour incubation with either 1 µg/mL or 10 µg/mL cumate (black 
and gray bars, respectively) to induce expression of KCNJ5 (A). Apoptosis was measured using an Annexin V assay after 24-hour incubation with 1 µg/mL 
cumate (B). Bars represent means of 6 separate experiments, error bars indicate SD. P values were calculated by ANOVA with a post hoc Bonferroni test, 
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adrenocortical cell proliferation with low-level transcrip-
tional induction of KCNJ5-T158A and, under similar condi-
tions, stimulation of apoptosis with KCNJ5-G151R, L168R, 
and G151E. In adenomas with KCNJ5 mutations, CYP11B2-
positive cells display strikingly reduced levels of KCNJ5 
expression compared with CYP11B2-negative cells of the 
same tumor and compared with CYP11B2-positive cells 
in APAs of other genotypes. We found decreased KCNJ5 
immunostaining in KCNJ5-mutated APAs compared with 
paired adjacent cortical tissue in agreement with a previous 
study which also showed the absence of KCNJ5 mutations in 
the adjacent cortex.28
Figure 3. Generation of KCNJ5 monoclonal antibodies. Monoclonal antibodies against KCNJ5 were produced by injection of mice with a synthetic peptide 
corresponding to the N-terminal portion of KCNJ5 (acetyl-36-ATDRTRLLAEGKKP-49-C). See methods for details. The specificity of antibodies KCNJ5-68-
15 and KCNJ5-33-11 was validated by Western blotting of cell lysates of HEK 293T cells transduced with a tetracycline-inducible lentivirus containing the 
human KCNJ5 sequence (A, uninduced [lanes 1 and 3] and tetracycline-induced [lanes 2 and 4]). KCNJ5 immunohistochemistry of adrenal cortex adjacent 
to an aldosterone-producing adenoma using KCNJ5-68-15 and KCNJ5-33–5 (B). KCNJ5-68-15 resulted in staining of most of the cortical tissue with evident 
staining of nuclei (B, left). KCNJ5-33–5 produced intense staining of the zona glomerulosa with clear localization to the plasma membrane (B, right). B, scale 
bar =100 µm. KCNJ5 indicates G-protein–coupled inwardly rectifying potassium channel.
Figure 4. Heterogeneous immunostaining 
of KCNJ5 in aldosterone-producing 
adenoma (APA) according to genotype. 
Immunohistochemical staining of KCNJ5 
and CYP11B2 in an APA with a KCNJ5 
mutation or in an APA with no mutation 
detected (NMD) showing decreased KCNJ5 
immunostaining in the adenoma with a KCNJ5 
mutation (A and B). APAs with ATP1A1, 
ATP2B3, or CACNA1D mutations displayed 
intense KCNJ5 immunostaining (C). Double 
immunofluorescence staining of KCNJ5 and 
CYP11B2 in an APA with a KCNJ5 mutation 
compared with a NMD-APA (D). KCNJ5 was 
intensely expressed in CYP11B2-negative cells 
in KCNJ5-mutated adenoma, but markedly 
decreased KCNJ5 immunofluorescence was 
observed in CYP11B2-positive cells (D, upper). 
In wild-type APAs, KCNJ5 and CYP11B2 
were colocalized to the same cells (D, lower). 
DAPI staining (blue) was only included in the 
merged image. A—C, scale bar =2 µm; D, 
scale bar =100 µm. ATP1A1 indicates Na+/K+ 
ATPase 1; ATP2B3, Ca2+ ATPase 3; CYP11B2, 
aldosterone synthase; CACNA1D, Cav1.3 
Ca2+ channel; and KCNJ5, G-protein–coupled 




 http://ahajournals.org by on Septem
ber 5, 2019
6  Hypertension  October 2019
These observations indicate that only low-level expres-
sion of KCNJ5 mutations is compatible with adrenocortical 
cell survival. KCNJ5 mutations are absent (or at least rarely 
found) in APCCs which comprise tight nests of zona glomeru-
losa cells.17 The cell toxicity of KCNJ5 mutations combined 
with the high KCNJ5 expression in the zona glomerulosa layer 
is consistent with the absence of KCNJ5 mutations in APCCs 
and the particular phenotype of KCNJ5-mutated APAs with a 
predominance of zona fasciculata cells over zona glomerulosa 
cells.29–31
It is unlikely that the differences in intensity of KCNJ5 
immunostaining are due to diminished antibody binding to 
mutated KCNJ5 because the monoclonal antibody was raised 
against a peptide corresponding to an extracellular N-terminal 
sequence at positions 36–49 (ATDRTRLLAEGKKP), far 
removed from the KCNJ5 mutations which are located in or 
near the channel pore region. Further, KCNJ5 immunohisto-
chemistry with a polyclonal antibody (binding to multiple epi-
topes) shows a similar reduction of KCNJ5 immunostaining 
compared with the adjacent cortex.28
As reported in other studies,4,12 APAs with KCNJ5 muta-
tions were larger than other APAs, and we show a positive 
correlation between nodule diameter of tumors with a KCNJ5-
G151R or L168R mutation with cell proliferation. The pro-
apoptotic effects of G151R and L168R and the relatively 
larger adenoma diameter of tumors carrying these mutations 
suggests a selective pressure to override apoptosis in these 
tumors. KCNJ5-mutated APAs have distinct transcriptional 
profiles compared with other APAs32–34 which may result in 
the expression of specific prosurvival factors to counteract 
the proapoptotic effects of KCNJ5-G151R and L168R.35–37 
Conversely, in NMD-APAs, a decreased Ki67 index was noted 
with increasing tumor diameter such that NMD-APAs with 
large tumor diameters displayed relatively lower Ki67 indices. 
This is probably due to a decline in proliferation rate during 
the lifespan of the tumor, as described previously for sporadic 
parathyroid adenomas,38 and potentially explained by the ac-
tivation of anti-proliferation and proapoptotic mechanisms to 
self-regulate tumor growth.
KCNJ5 potassium channel mutations associated with PA 
display a loss of selectivity for potassium ions and aberrant 
sodium ion conductance.2,5 This disturbance in channel con-
ductance appears less severe in with KCNJ5-T158A because 
human embryonic kidney cells expressing this mutant display 
an increased permeability ratio for potassium relative to so-
dium ions compared with cells expressing G151R or L168R.2 
Transduction of human adrenocortical cells with a lentivirus 
carrying the cDNA encoding the KCNJ5-T158A channel 
resulted in a decrease in cell proliferation compared with con-
trol cells.5 Our data with the higher level of transcriptional 
induction of KCNJ5 concord with the observations of Oki et 
al,5 but we did observe an increase in cell proliferation when 
Figure 6. KCNJ5 and CYP11B2 
immunostaining of aldosterone-producing cell 
clusters. Immunohistochemistry (A) and double 
immunofluorescence (B) showed intense 
KCNJ5 staining in aldosterone-producing cell 
clusters and colocalization with CYP11B2. 
DAPI (blue) was only included in the merged 
image. Scale bar =100 µm. CYP11B2 indicates 
aldosterone synthase; and KCNJ5, G-protein–
coupled inwardly rectifying potassium channel.
Figure 5. KCNJ5 immunostaining in aldosterone-
producing adenomas (APAs) according to 
genotype. Semi-quantitative H score of KCNJ5 
immunohistochemistry in adenomas according to 
genotype is shown (A). Horizontal Lines represent 
median, vertical lines represent range (A). P value was 
calculated by the Mann-Whitney U test, ****difference 
(P<0.0001) from no mutation detected (NMD) or from 
other mutations combined. Relatively lower KCNJ5 
immunostaining was noted in all adenomas with a 
KCNJ5 mutation compared with paired adjacent cortex, 
whereas 75% of 20 adenomas with other genotypes 
combined (NMD, n=10; ATP1A1, n=3; ATP2B2, n=2; 
and CACNA1D, n=5) showed either increased or similar 
expression in APAs compared with paired adjacent 
cortex (B). NMD, no mutation detected; other, adenomas 
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the level of induction of KCNJ5-T158A gene expression was 
decreased.
Germline variants of KCNJ5 cause a familial form of PA 
called FH type III (familial hyperaldosteronism type III).39 
Patients with germline KCNJ5-T158A or G151R mutations 
present with a severe form of PA with extensive adrenocortical 
hyperplasia requiring bilateral adrenalectomy.2,16,40 Patients 
with FH type III with a KCNJ5-G151E mutation display a rel-
atively mild, medically-treatable clinical phenotype with ap-
parently normal adrenals from computerized tomography scan 
results.41 Patch-clamp electrophysiology of human embry-
onic kidney 293T cells transfected with KCNJ5-G151E and 
G151R, demonstrated the increased sodium ion conductance 
of the G151E mutated channel and cell survival assays estab-
lished the greater cell lethality induced by G151E relative to 
G151R.41 Our study supports this suggestion because KCNJ5-
G151E, but not G151R, caused a highly significant reduction 
in the viability of human adrenocortical cells. The increased 
cell toxicity associated with KCNJ5-G151E was inferred to 
limit adrenocortical cell mass and account for the milder phe-
notype of carriers of this germline variant41 probably because 
only a subset of cells expressing low-levels of the mutated 
channel can survive and produce excess aldosterone.
Strengths and Limitations of the Study
The strength of our study is the production of stable human 
adrenocortical cell lines with inducible expression of KCNJ5 
mutations to study the cell growth effects of sporadic and 
germline KCNJ5 mutations. A further strength is the anal-
ysis of the proliferative status of a large cohort of APAs with 
genotype data that were homogeneously selected for surgery 
according to a stringent diagnostic flow chart that included 
adrenal venous sampling. Finally, we used highly specific 
monoclonal antibodies to demonstrate by immunohistochem-
istry and double immunofluorescence the variance in KCNJ5 
and CYP11B2 expression in APAs according to genotype. 
A limitation of our study is that genotyping was performed 
on dissected pieces of adrenal nodule rather than targeted to 
CYP11B2 expressing regions. However, we minimized the 
potential genotyping of a nonfunctional nodule because we 
performed CYP11B2 immunochemistry of all adrenals in-
cluded in the study and those with nonfunctional nodules were 
excluded.
Perspectives
KCNJ5 mutations cause cell lethality to a variable degree 
according to genotype and expression level. The proliferative 
function of KCNJ5 mutations in vivo is challenging to repro-
duce in vitro because any long-term chronic effects of poten-
tial survival factors are difficult to replicate in adrenal cell 
cultures. Transcriptome studies are planned to identify genes 
and signaling pathways which enable cell proliferation of 
adenomas with KCNJ5 mutations, despite the increased cell 
lethality caused by their expression, and which limit growth 
rates of tumors with NMD.
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What Is New?
•	Ki67 proliferation index is positively correlated with adenoma diameter 
in KCNJ5-mutated aldosterone-producing adenomas, a negative corre-
lation was noted in tumors with no mutation detected.
•	Adrenocortical cell expression of the sporadic and germline KCNJ5-
T158A mutation caused cell proliferation at low induction of expression, 
other KCNJ5 mutations induced apoptosis.
•	The zona glomerulosa layer and aldosterone-producing cell clusters ad-
jacent to adenomas show intense KCNJ5 immunostaining.
•	KCNJ5-mutated adenomas comprise CYP11B2-positive cells with a 
marked reduction of KCNJ5 immunostaining compared with CYP11B2-
negative cells and aldosterone-producing adenomas of other genotype.
What Is Relevant?
•	KCNJ5 mutations in aldosterone-producing adenomas are associated 
with increased adrenal cell proliferation.
•	KCNJ5 mutations may be absent from aldosterone-producing cell clus-
ters due to the high-level of KCNJ5 expression in the zona glomerulosa.
Summary
KCNJ5 mutations induce cell toxicity and their effects on adreno-
cortical cell growth are determined in part by the expression level 
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